Business · 02/03/2018

FDA Releases Draft Guidance on Definitions of Suspect and Illegitimate Products for Verification Obligations Under the Drug Supply Chain Security Act

The Food and Drug Administration (FDA) has released a draft guidance outlining its interpretation of key terms related to suspect and illegitimate products under the Drug Supply Chain Security Act, aiming to clarify verification obligations for trading partners.